S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy

Amicus Therapeutics (FOLD) Competitors

$13.56
-0.14 (-1.02%)
(As of 02/21/2024 ET)

FOLD vs. MDGL, ALKS, IRWD, BBIO, DVAX, LGND, GERN, INVA, IONS, and ALLK

Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ironwood Pharmaceuticals (IRWD), BridgeBio Pharma (BBIO), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Geron (GERN), Innoviva (INVA), Ionis Pharmaceuticals (IONS), and Allakos (ALLK). These companies are all part of the "pharmaceutical preparations" industry.

Amicus Therapeutics vs.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

79.9% of Madrigal Pharmaceuticals shares are held by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amicus Therapeutics received 76 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 73.38% of users gave Amicus Therapeutics an outperform vote while only 68.56% of users gave Madrigal Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Madrigal PharmaceuticalsOutperform Votes
434
68.56%
Underperform Votes
199
31.44%
Amicus TherapeuticsOutperform Votes
510
73.38%
Underperform Votes
185
26.62%

In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than Amicus Therapeutics. MarketBeat recorded 13 mentions for Madrigal Pharmaceuticals and 11 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 0.77 beat Madrigal Pharmaceuticals' score of -0.05 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amicus Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Madrigal Pharmaceuticals presently has a consensus price target of $304.00, suggesting a potential upside of 33.19%. Amicus Therapeutics has a consensus price target of $17.20, suggesting a potential upside of 26.84%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Amicus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Amicus Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -46.61%. Madrigal Pharmaceuticals' return on equity of -147.61% beat Amicus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal PharmaceuticalsN/A -293.56% -112.46%
Amicus Therapeutics -46.61%-147.61%-23.79%

Amicus Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A-$295.35M-$19.24-11.86
Amicus Therapeutics$329.23M12.08-$236.57M-$0.59-22.98

Madrigal Pharmaceuticals has a beta of -0.48, meaning that its share price is 148% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

Madrigal Pharmaceuticals beats Amicus Therapeutics on 9 of the 17 factors compared between the two stocks.


Get Amicus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FOLD vs. The Competition

MetricAmicus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.98B$6.68B$4.97B$7.34B
Dividend YieldN/A2.75%2.92%3.85%
P/E Ratio-22.9818.21119.7318.18
Price / Sales12.08140.432,966.6357.77
Price / CashN/A18.5090.8154.06
Price / Book30.824.424.304.56
Net Income-$236.57M$156.98M$112.59M$207.35M
7 Day Performance2.88%1.37%1.63%0.64%
1 Month Performance12.72%9.95%7.20%4.52%
1 Year Performance5.28%-0.88%7.09%3.76%

Amicus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDGL
Madrigal Pharmaceuticals
4.8004 of 5 stars
$204.80
-5.3%
$309.14
+50.9%
-21.0%$4.04BN/A-10.6492Gap Down
ALKS
Alkermes
4.3509 of 5 stars
$27.23
-4.5%
$32.43
+19.1%
+5.1%$4.54B$1.11B21.962,280Earnings Report
Analyst Downgrade
Buyback Announcement
Analyst Revision
IRWD
Ironwood Pharmaceuticals
4.4136 of 5 stars
$15.20
-1.1%
$20.60
+35.5%
+30.1%$2.37B$410.60M-2.44219Analyst Upgrade
Analyst Revision
Positive News
Gap Down
BBIO
BridgeBio Pharma
4.0153 of 5 stars
$33.57
-5.8%
$42.00
+25.1%
+186.6%$5.84B$77.65M-8.61392Gap Down
DVAX
Dynavax Technologies
4.5388 of 5 stars
$12.29
-4.1%
$25.00
+103.4%
+16.1%$1.59B$722.68M31.51351Positive News
Gap Down
LGND
Ligand Pharmaceuticals
3.5306 of 5 stars
$71.00
-6.1%
$116.33
+63.8%
+2.5%$1.23B$196.24M104.4176Upcoming Earnings
GERN
Geron
3.3081 of 5 stars
$2.07
-12.7%
$4.67
+125.4%
-30.1%$1.12B$600,000.00-6.09107Gap Down
INVA
Innoviva
1.8557 of 5 stars
$15.48
-1.5%
$15.17
-2.0%
+27.6%$992.11M$331.34M35.18101Upcoming Earnings
IONS
Ionis Pharmaceuticals
3.5394 of 5 stars
$48.61
-3.5%
$49.80
+2.4%
+13.9%$6.97B$587M-16.94796Earnings Report
Analyst Report
News Coverage
Positive News
Gap Down
ALLK
Allakos
4.5654 of 5 stars
$1.27
-8.6%
$9.42
+641.5%
-78.9%$111.10MN/A-0.66123Gap Down

Related Companies and Tools

This page (NASDAQ:FOLD) was last updated on 2/22/2024 by MarketBeat.com Staff